BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22006831)

  • 41. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
    Pietrzyk B; Smertka M; Chudek J
    Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.
    Mirza FS; Padhi ID; Raisz LG; Lorenzo JA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1991-7. PubMed ID: 20156921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
    Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; GuaƱabens N; Peris P
    Osteoporos Int; 2015 Sep; 26(9):2273-80. PubMed ID: 25939310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody.
    Morrell AE; Robinson ST; Ke HZ; Holdsworth G; Guo XE
    Bone; 2021 Aug; 149():115967. PubMed ID: 33892178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women.
    Durosier C; van Lierop A; Ferrari S; Chevalley T; Papapoulos S; Rizzoli R
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3873-83. PubMed ID: 23864703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training.
    Armamento-Villareal R; Sadler C; Napoli N; Shah K; Chode S; Sinacore DR; Qualls C; Villareal DT
    J Bone Miner Res; 2012 May; 27(5):1215-21. PubMed ID: 22392834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
    Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
    Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
    Pelletier S; Confavreux CB; Haesebaert J; Guebre-Egziabher F; Bacchetta J; Carlier MC; Chardon L; Laville M; Chapurlat R; London GM; Lafage-Proust MH; Fouque D
    Osteoporos Int; 2015 Aug; 26(8):2165-74. PubMed ID: 25910747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures.
    Heilmeier U; Carpenter DR; Patsch JM; Harnish R; Joseph GB; Burghardt AJ; Baum T; Schwartz AV; Lang TF; Link TM
    Osteoporos Int; 2015 Apr; 26(4):1283-93. PubMed ID: 25582311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
    Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
    J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
    Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
    J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
    Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Effects of Exercise and Activity-Based Physical Therapy on Bone after Spinal Cord Injury.
    Sutor TW; Kura J; Mattingly AJ; Otzel DM; Yarrow JF
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with hydrogen sulfide attenuates sublesional skeletal deterioration following motor complete spinal cord injury in rats.
    Yang X; Hao D; Zhang H; Liu B; Yang M; He B
    Osteoporos Int; 2017 Feb; 28(2):687-695. PubMed ID: 27591786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient-specific bone mineral density distribution in the tibia of individuals with chronic spinal cord injury, derived from multi-slice peripheral Quantitative Computed Tomography (pQCT) - A cross-sectional study.
    Coupaud S; Gislason MK; Purcell M; Sasagawa K; Tanner KE
    Bone; 2017 Apr; 97():29-37. PubMed ID: 28034635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
    Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
    Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreases in bone mineral density at cortical and trabecular sites in the tibia and femur during the first year of spinal cord injury.
    Coupaud S; McLean AN; Purcell M; Fraser MH; Allan DB
    Bone; 2015 May; 74():69-75. PubMed ID: 25596521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.